LGND – Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals IncorporLGND
$201.35Name : Ligand Pharmaceuticals Incorpor
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,962,914,560.00
EPSttm : 2.27
Ligand Pharmaceuticals Incorpor
$201.35
0.24%$0.49Float Short %
5.77
Margin Of Safety %
-26
Put/Call OI Ratio
0.47
EPS Next Q Diff
-1.56
EPS Last/This Y
7.85
EPS This/Next Y
0.3
Price
201.1
Target Price
228.12
Analyst Recom
1
Performance Q
30.69
Relative Volume
1.23
Beta
1.02
Ticker: LGND
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-10-20 | LGND | 186.74 | 0.47 | 999.99 | 913 |
| 2025-10-21 | LGND | 186.9 | 0.47 | 3.00 | 913 |
| 2025-10-22 | LGND | 185.77 | 0.48 | 0.00 | 916 |
| 2025-10-23 | LGND | 185.14 | 0.48 | 999.99 | 918 |
| 2025-10-24 | LGND | 186.85 | 0.48 | 5.00 | 918 |
| 2025-10-27 | LGND | 189.93 | 0.47 | 0.36 | 910 |
| 2025-10-28 | LGND | 188.23 | 0.46 | 0.00 | 921 |
| 2025-10-29 | LGND | 184.98 | 0.46 | 0.00 | 922 |
| 2025-10-30 | LGND | 186.88 | 0.46 | 0.00 | 921 |
| 2025-10-31 | LGND | 191.32 | 0.45 | 0.06 | 926 |
| 2025-11-03 | LGND | 191.13 | 0.45 | 0.00 | 939 |
| 2025-11-04 | LGND | 189.54 | 0.45 | 0.00 | 940 |
| 2025-11-05 | LGND | 190.4 | 0.45 | 999.99 | 941 |
| 2025-11-06 | LGND | 208.12 | 0.47 | 0.23 | 954 |
| 2025-11-07 | LGND | 202.49 | 0.48 | 0.00 | 970 |
| 2025-11-10 | LGND | 209.3 | 0.48 | 0.00 | 970 |
| 2025-11-11 | LGND | 208.32 | 0.48 | 0.38 | 971 |
| 2025-11-12 | LGND | 205.64 | 0.48 | 0.10 | 980 |
| 2025-11-13 | LGND | 201.23 | 0.46 | 999.99 | 999 |
| 2025-11-14 | LGND | 200.89 | 0.46 | 0.00 | 1000 |
| 2025-11-17 | LGND | 201.14 | 0.47 | 0.24 | 998 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-10-20 | LGND | 186.74 | 4.4 | 213.9 | 6.92 |
| 2025-10-21 | LGND | 186.71 | 4.4 | 209.9 | 6.92 |
| 2025-10-22 | LGND | 185.57 | 4.4 | 209.1 | 6.92 |
| 2025-10-23 | LGND | 184.82 | 4.4 | 209.4 | 6.92 |
| 2025-10-24 | LGND | 186.70 | 4.4 | 211.0 | 6.92 |
| 2025-10-27 | LGND | 189.96 | 4.4 | 212.2 | 6.92 |
| 2025-10-28 | LGND | 188.87 | 4.4 | 209.2 | 6.92 |
| 2025-10-29 | LGND | 184.64 | 4.4 | 206.8 | 6.92 |
| 2025-10-30 | LGND | 187.06 | 4.4 | 211.7 | 6.92 |
| 2025-10-31 | LGND | 191.31 | 4.4 | 213.1 | 6.92 |
| 2025-11-03 | LGND | 191.42 | 4.4 | 210.0 | 6.92 |
| 2025-11-04 | LGND | 189.72 | 4.4 | 209.0 | 6.92 |
| 2025-11-05 | LGND | 190.12 | 4.4 | 210.5 | 6.92 |
| 2025-11-06 | LGND | 207.71 | 2.6 | 222.8 | 6.87 |
| 2025-11-07 | LGND | 202.48 | 2.6 | 205.4 | 6.87 |
| 2025-11-10 | LGND | 209.29 | 27.0 | 214.6 | 6.87 |
| 2025-11-11 | LGND | 208.70 | 27.0 | 16.1 | 7.37 |
| 2025-11-12 | LGND | 205.55 | 27.0 | 15.0 | 7.37 |
| 2025-11-13 | LGND | 201.27 | 21.1 | 14.5 | 7.63 |
| 2025-11-14 | LGND | 200.76 | 21.1 | 16.1 | 7.63 |
| 2025-11-17 | LGND | 201.10 | 21.1 | 16.4 | 7.63 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-10-20 | LGND | -0.67 | 2.52 | 6.26 |
| 2025-10-21 | LGND | -0.67 | 2.52 | 6.26 |
| 2025-10-22 | LGND | -0.67 | 2.52 | 6.26 |
| 2025-10-23 | LGND | -0.67 | 2.52 | 6.26 |
| 2025-10-24 | LGND | -0.67 | 2.52 | 6.26 |
| 2025-10-27 | LGND | -0.67 | 2.35 | 6.18 |
| 2025-10-28 | LGND | -0.67 | 2.35 | 6.18 |
| 2025-10-29 | LGND | -0.67 | 2.35 | 6.18 |
| 2025-10-30 | LGND | -0.67 | 2.35 | 6.18 |
| 2025-10-31 | LGND | -0.67 | 2.35 | 6.18 |
| 2025-11-03 | LGND | -0.67 | 2.96 | 6.18 |
| 2025-11-04 | LGND | -0.67 | 2.96 | 6.18 |
| 2025-11-05 | LGND | -0.67 | 2.96 | 6.18 |
| 2025-11-06 | LGND | -0.76 | 2.96 | 6.18 |
| 2025-11-07 | LGND | -0.76 | 2.96 | 6.18 |
| 2025-11-10 | LGND | -0.76 | 2.78 | 6.18 |
| 2025-11-11 | LGND | -0.76 | 2.78 | 6.18 |
| 2025-11-12 | LGND | -2.85 | 2.78 | 5.77 |
| 2025-11-13 | LGND | -2.85 | 2.78 | 5.77 |
| 2025-11-14 | LGND | -4.90 | 2.78 | 5.77 |
| 2025-11-17 | LGND | -5.07 | 3.15 | 5.77 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
3.09
Avg. EPS Est. Current Quarter
1.54
Avg. EPS Est. Next Quarter
1.53
Insider Transactions
-5.07
Institutional Transactions
3.15
Beta
1.02
Average Sales Estimate Current Quarter
55
Average Sales Estimate Next Quarter
52
Fair Value
148.51
Quality Score
85
Growth Score
62
Sentiment Score
79
Actual DrawDown %
5.4
Max Drawdown 5-Year %
-65.5
Target Price
228.12
P/E
96.91
Forward P/E
25.41
PEG
5.06
P/S
15.77
P/B
4.17
P/Free Cash Flow
129.34
EPS
2.08
Average EPS Est. Cur. Y
7.63
EPS Next Y. (Est.)
7.92
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
19.34
Relative Volume
1.23
Return on Equity vs Sector %
-21.8
Return on Equity vs Industry %
-6.9
EPS 1 7Days Diff
0.7
EPS 1 30Days Diff
0.68
EBIT Estimation
16.4
Ligand Pharmaceuticals IncorporSector: Healthcare
Industry: Biotechnology
Employees: 68
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
stock quote shares LGND – Ligand Pharmaceuticals Incorporated Stock Price stock today
news today LGND – Ligand Pharmaceuticals Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch LGND – Ligand Pharmaceuticals Incorporated yahoo finance google finance
stock history LGND – Ligand Pharmaceuticals Incorporated invest stock market
stock prices LGND premarket after hours
ticker LGND fair value insiders trading